ERBB2 and breast carcinoma: Furthermore, activation of the IL-6 inflammatory loop induces trastuzumab-resistance in HER2+ breast cancer cells indicating that IL-6’s pro-inflammatory role mediates breast cancer therapeutic resistance (122).